Michael Eichbaum

Prof. Dr. Michael Eichbaum

Helios Dr. Horst-Schmidt-Kliniken Wiesbaden, Department of Gynecology and Obstetrics

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Ludwig KieselLudwig Kiesel
Ludwig Kiesel
CEChristine Eichbaum
Christine Eichbaum
ABAriane Baumeier
Ariane Baumeier
Michael EichbaumMichael Eichbaum
Michael Eichbaum
Endometrial cancer (EC) is the most frequently observed malignant gynecologic disease in developed countries. There is a strong association between the established risk factor obesity and the incidence of EC. Furthermore, the rate of women with a body mass index (BMI) > 30 kg/m2 is increasing worldwide, correspondingly leading to a higher prevalence of EC. Understanding the adipose tissue as an endocrine organ, elementary pathophysiological pathways of tumorigenesis have been revealed. This includes the fundamental role of hyperglycemia, insulin resistance, and hyperestrogenemia, as well as interactions with a chronic proinflammatory microenvironment. Therapeutic options potentially include metformin or bariatric surgery. Moreover, changes in individual lifestyle such as weight reduction, physical activity, and an awareness of healthy nutrition are effective in preventing the disease.

1 February 2011 in Cancer
Verified
Journal Article
Open access
PDF file
Michael EichbaumMichael Eichbaum
Michael Eichbaum
CSChristof Sohn
Christof Sohn
Click on the article title to read more.

14 February 2023 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
Michael EichbaumMichael Eichbaum
Michael Eichbaum
IMIvo Mitsiev
Ivo Mitsiev
RKRainer Kimmig
Rainer Kimmig
CEChristine Eichbaum
Christine Eichbaum
HAHoria Asrar
Horia Asrar

1 January 2008 in Breast Care
Verified
Journal Article
Open access
PDF file
VMVolkmar Müller
Volkmar Müller
RGRichard Greil
Richard Greil
Marcus SchmidtMarcus Schmidt
Marcus Schmidt
WJWolfgang Janni
Wolfgang Janni
BRBrigitte Rack
Brigitte Rack
PSPiero Sismondi
Piero Sismondi

19 September 2006 in Geburtshilfe und Frauenheilkunde
Verified
Journal Article
Closed access
GGG. Gebauer
G. Gebauer
JSJ. Schleibaum
J. Schleibaum
SAS. Aulmann
S. Aulmann
Michael EichbaumMichael Eichbaum
Michael Eichbaum
PSP. Schirmacher
P. Schirmacher
Hans-Peter SinnHans-Peter Sinn
Hans-Peter Sinn
Introduction: Vulvar cancer develops from precursor lesions known as vulvar intraepithelial neoplasia (VIN) which frequently occur simultaneously in multiple locations and have a considerable risk or recurrence during follow-up. Invasive squamous carcinomas of the vulva frequently harbor gains on the long arm of chromosome 3, including the human telomerase gene locus (TERC). Activation of telomerase, the enzyme that synthesizes the telomere ends of linear chromosomes, has been implicated in human cell immortalization and cancer cell pathogenesis. We investigated TERC gene copy number in a series of vulvar intraepithelial neoplasias to determine the risk of progression in these lesions. Material and Methods: A total of 20 cases of high grade vulvar intraepithelial neoplasias (VIN 3) were analyzed using a two-color fluorescence in situ hybridization (FISH) assay detecting the human telomerase gene locus (3q26) on paraffin embedded tissue sections (Cancer Genetics Inc. Milford, MA, USA). Prior to FisH all samples were verified by the same pathologist (P.S.) in order to ensure homogenous classification of the dysplastic lesions. Results: Two samples were excluded for technical reasons. In 11 cases, gains of chromosomal material at 3q26 were detected with an average of 1.48 copies per chromosome. In another patient a high level amplification was found. The remaining two cases, four centromere and 3q26 hybridization signals were observed, consistent with a tetraploidy of chromosome 3. No changes in DNA copy number on chromosome 3q were detected only in four lesions. Conclusion: Our findings demonstrate a high frequency of gains on chromosome 3q in the majority of high grade vulvar lesions suggesting a pathogenetic role of the human telomerase gene locus for neoplastic but also preneoplastic lesions of the vulva.

12 October 2021 in International Journal of Gynecological Cancer
Verified
Conference Paper
Open access
PDF file
DDD Denschlag
D Denschlag
FHFlorian Dr. Heitz
Florian Dr. Heitz
JPJacobus Pfisterer
Jacobus Pfisterer
DTD Tutschkow
D Tutschkow
WMW Meier
W Meier
ABA Du Bois
A Du Bois
Introduction/Background*There is poor evidence from mostly retrospective series whether co-medication with metformin, statin or beta-blocker have an impact on survival in patients with primary ovarian cancer. The aim of this study was to investigate the association of these medications with survival. Methodology Individual data from 3 prospective phase III randomized controlled trials (AGO-OVAR 11/ICON 7, 12, 16) and one phase II trial (AGO-OVAR 15) were pooled and analyzed. Patients were either classified as “ever-user” if the specific co-medication was documented at least once during the trial. In. contrast, “never-users” served as controls. Data were adjusted for potential confounders (age, FIGO stage, histology, residual tumor after surgery, ECOG performance status, BMI, Charlson Comorbidity Index and assigned treatment within the trial) in multivariate Cox regression analyses. Result(s)*Overall, 2.857 patients were included in the analyses. “Ever-users” were: N=100 patients received metformin (3.5%), N=226 received statins (7.9%), and N=475 (16.6%) received beta-blockers (BB) (N=391 selective (sBB); N=84 non-selective (nsBB)) as co-medication. There were no significant differences regarding the baseline characteristics (histology, FIGO stage, residual tumor after surgery, and chemotherapy-schedule) between “ever- and never-users” except that “ever-users” were significantly older and more obese, compared to controls. Median progression-free (PFS) and overall survival (OS) for the entire cohort was 18.7 months and 60.1 months, respectively Multivariate analyses for PFS and OS including age, BMI, Histology, FIGO stage, residual tumor after surgery, ECOG performance status and CCI revealed neither a significant impact of metformin on survival of “ever-users”, compared to “never-users” (PFS HR 0.94 95%-CI 0.69-1.29, p=0.7; OS HR 0.82 95%-CI 0.58-1.17, p=0.28), nor for statins (PFS HR 0.98 95%-CI 0.82-1.18, p=0.87; OS HR 0.91 95%-CI 0.74-1.12, p=0.37), respectively. In contrast, “ever-users” of sBB had a significantly elevated risk for recurrence and death in multivariate analysis (PFS HR 1.22 95%-CI 1.05-1.41, p=0.009; OS HR 1.25 95%-CI 1.06-1.47, p=0.009). Conclusion*In this large pooled analysis neither a co-medication with metformin nor with statins had a significant impact on survival in patients with primary ovarian cancer. In contrast, co-medication with a beta-blocker was associated with worse survival. Further studies are warranted to confirm this observation.